20
02, 2024
14
02, 2024
Lorenza Rimassa et al., Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
adlitterio663392024-04-10T14:35:43+02:00
11
02, 2024
2
02, 2024
27
01, 2024
19
01, 2024
17
01, 2024
8
01, 2024
6
01, 2024
3
01, 2024